ID   FaDu
AC   CVCL_1218
DR   BTO; BTO:0003233
DR   CLO; CLO_0002993
DR   EFO; EFO_0002178
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BCRC; 60214
DR   BCRJ; 0301
DR   BioGRID_ORCS_Cell_line; 676
DR   BioSample; SAMN03471972
DR   BioSample; SAMN10987898
DR   cancercelllines; CVCL_1218
DR   CCRID; 3101HUMTCHu132
DR   Cell_Model_Passport; SIDM00860
DR   ChEMBL-Cells; CHEMBL3307943
DR   ChEMBL-Targets; CHEMBL612250
DR   CLS; 305033
DR   Cosmic; 686975
DR   Cosmic; 906863
DR   Cosmic; 921832
DR   Cosmic; 1006466
DR   Cosmic; 1017792
DR   Cosmic; 1122668
DR   Cosmic; 1339914
DR   Cosmic; 1530736
DR   Cosmic; 1752764
DR   Cosmic; 2301587
DR   Cosmic; 2592979
DR   Cosmic; 2646650
DR   Cosmic; 2668290
DR   Cosmic-CLP; 906863
DR   DepMap; ACH-000846
DR   DSMZ; ACC-784
DR   DSMZCellDive; ACC-784
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 906863
DR   GEO; GSM482707
DR   GEO; GSM482708
DR   GEO; GSM482709
DR   GEO; GSM482710
DR   GEO; GSM887011
DR   GEO; GSM888080
DR   GEO; GSM1374479
DR   GEO; GSM1374480
DR   GEO; GSM1524310
DR   GEO; GSM1524311
DR   GEO; GSM1524312
DR   GEO; GSM1669791
DR   GEO; GSM5104698
DR   GEO; GSM5104717
DR   IARC_TP53; 1681
DR   IGRhCellID; FaDu
DR   KCLB; 30043
DR   LiGeA; CCLE_224
DR   PharmacoDB; FADU_365_2019
DR   PRIDE; PXD002132
DR   PRIDE; PXD002486
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1218
DR   PubChem_Cell_line; CVCL_1218
DR   Wikidata; Q54833221
RX   CelloPub=CLPUB00484;
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1394225;
RX   PubMed=2990217;
RX   PubMed=3138611;
RX   PubMed=3518877;
RX   PubMed=4332311;
RX   PubMed=6935474;
RX   PubMed=7459858;
RX   PubMed=8552396;
RX   PubMed=9815580;
RX   PubMed=11799138;
RX   PubMed=17848307;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21833476;
RX   PubMed=21868764;
RX   PubMed=22460905;
RX   PubMed=23613873;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25888065;
RX   PubMed=26122845;
RX   PubMed=26589293;
RX   PubMed=26754630;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28476783;
RX   PubMed=28844650;
RX   PubMed=29156801;
RX   PubMed=30135316;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31541927;
RX   PubMed=31978347;
RX   PubMed=33802339;
RX   PubMed=34249502;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Indian.
CC   Doubling time: ~50 hours (Note=At 16th passage) (PubMed=4332311); ~30 hours (DSMZ=ACC-784).
CC   HLA typing: A*01:01,01:01; B*15:17,37:04; C*07:01,07:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (ATCC=HTB-43; Cosmic-CLP=906863; DepMap=ACH-000846).
CC   Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (Cosmic-CLP=906863; DepMap=ACH-000846).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC=HTB-43; Cosmic-CLP=906863; DepMap=ACH-000846).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC=HTB-43; Cosmic-CLP=906863; DepMap=ACH-000846).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced (low read coverage).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.06%; Native American=0%; East Asian, North=11.01%; East Asian, South=0%; South Asian=79.51%; European, North=0%; European, South=7.42% (PubMed=30894373).
CC   Derived from site: In situ; Pharynx, hypopharynx; UBERON=UBERON_0001051.
ST   Source(s): ATCC=HTB-43; Cosmic-CLP=906863; DSMZ=ACC-784; Technion Genomics Center BCF; KCLB=30043; PubMed=21868764; PubMed=25877200; PubMed=33802339
ST   Amelogenin: Not_detected (ATCC=HTB-43; Cosmic-CLP=906863; DSMZ=ACC-784; Technion Genomics Center BCF; PubMed=21868764; PubMed=25877200; PubMed=33802339)
ST   Amelogenin: X (KCLB=30043)
ST   CSF1PO: 12
ST   D10S1248: 15,17
ST   D12S391: 17,21
ST   D13S317: 8,9 (ATCC=HTB-43; Technion Genomics Center BCF; PubMed=21868764; PubMed=25877200; PubMed=33802339)
ST   D13S317: 9 (DSMZ=ACC-784)
ST   D16S539: 11 (ATCC=HTB-43; Cosmic-CLP=906863; Technion Genomics Center BCF; PubMed=21868764; PubMed=25877200; PubMed=33802339)
ST   D16S539: 11,12 (DSMZ=ACC-784)
ST   D18S51: 16
ST   D19S433: 14,16
ST   D1S1656: 16,16.3
ST   D21S11: 31 (DSMZ=ACC-784)
ST   D21S11: 31.2 (ATCC=HTB-43; Technion Genomics Center BCF; PubMed=25877200; PubMed=33802339)
ST   D22S1045: 11
ST   D2S1338: 19
ST   D2S441: 11
ST   D3S1358: 17,18
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 13
ST   FGA: 25
ST   Penta D: 11
ST   Penta E: 17,19
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 15,17 (ATCC=HTB-43; Cosmic-CLP=906863; Technion Genomics Center BCF; KCLB=30043; PubMed=21868764; PubMed=25877200)
ST   vWA: 15,17,18 (DSMZ=ACC-784; PubMed=33802339)
DI   NCIt; C4043; Hypopharyngeal squamous cell carcinoma
DI   ORDO; Orphanet_494547; Squamous cell carcinoma of the hypopharynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 45
RX   CelloPub=CLPUB00484;
RA   Xu Z.-H., Sun W.-W., Hang J.-B., Gao B.-L., Hu J.-A.;
RT   "RNA-seq identified a novel functional MET fusion in head and neck
RT   cancer 5-8F cell line.";
RL   Int. J. Clin. Exp. Pathol. 9:8308-8317(2016).
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York (1994).
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RX   PubMed=2990217;
RA   Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.;
RT   "Presence and expression of human papillomavirus sequences in human
RT   cervical carcinoma cell lines.";
RL   Am. J. Pathol. 119:361-366(1985).
RX   PubMed=3138611; DOI=10.1177/019459988809800603;
RA   Wustrow T.P.U., Raffael A., Valet G.K.;
RT   "Multiparametric flow cytometry of human squamous cell carcinoma lines
RT   from the head and neck.";
RL   Otolaryngol. Head Neck Surg. 98:552-557(1988).
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
RX   PubMed=4332311; DOI=10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R;
RA   Rangan S.R.S.;
RT   "A new human cell line (FaDu) from a hypopharyngeal carcinoma.";
RL   Cancer 29:117-121(1972).
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
RX   PubMed=8552396;
RA   Patel A.M., Incognito L.S., Schechter G.L., Wasilenko W.J.,
RA   Somers K.D.;
RT   "Amplification and expression of EMS-1 (cortactin) in head and neck
RT   squamous cell carcinoma cell lines.";
RL   Oncogene 12:31-35(1996).
RX   PubMed=9815580;
RA   Wu Y.-G., Palad A.J., Wasilenko W.J., Blackmore P.F., Pincus W.A.,
RA   Schechter G.L., Spoonster J.R., Kohn E.C., Somers K.D.;
RT   "Inhibition of head and neck squamous cell carcinoma growth and
RT   invasion by the calcium influx inhibitor carboxyamido-triazole.";
RL   Clin. Cancer Res. 3:1915-1921(1997).
RX   PubMed=11799138; DOI=10.1177/002215540205000207;
RA   Eicheler W., Zips D., Dorfler A., Grenman R., Baumann M.;
RT   "Splicing mutations in TP53 in human squamous cell carcinoma lines
RT   influence immunohistochemical detection.";
RL   J. Histochem. Cytochem. 50:197-204(2002).
RX   PubMed=17848307; DOI=10.1016/j.ijrobp.2007.04.082;
RA   Yarbrough W.G., Whigham A., Brown B., Roach M., Slebos R.J.C.;
RT   "Phosphoinositide kinase-3 status associated with presence or absence
RT   of human papillomavirus in head and neck squamous cell carcinomas.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 69:S98-S101(2007).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=21833476; DOI=10.3892/or.2011.1418;
RA   Ma J.-K., Lu S.-M., Yu L., Tian J.-J., Li J.-F., Wang H.-B., Xu W.;
RT   "FaDu cell characteristics induced by multidrug resistance.";
RL   Oncol. Rep. 26:1189-1195(2011).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=23613873; DOI=10.1371/journal.pone.0061555;
RA   Martens-de Kemp S.R., Dalm S.U., Wijnolts F.M.J., Brink A.,
RA   Honeywell R.J., Peters G.J., Braakhuis B.J.M., Brakenhoff R.H.;
RT   "DNA-bound platinum is the major determinant of cisplatin sensitivity
RT   in head and neck squamous carcinoma cells.";
RL   PLoS ONE 8:E61555-E61555(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008;
RA   Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M.,
RA   Simons A.L.;
RT   "Upregulated interleukin-6 expression contributes to erlotinib
RT   resistance in head and neck squamous cell carcinoma.";
RL   Mol. Oncol. 9:1371-1383(2015).
RX   PubMed=26122845; DOI=10.1158/0008-5472.CAN-15-0528;
RA   Stoepker C., Ameziane N., van der Lelij P., Kooi I.E., Oostra A.B.,
RA   Rooimans M.A., van Mil S.E., Brink A., Dietrich R., Balk J.A.,
RA   Ylstra B., Joenje H., Feller S.M., Brakenhoff R.H.;
RT   "Defects in the Fanconi anemia pathway and chromatid cohesion in head
RT   and neck cancer.";
RL   Cancer Res. 75:3543-3553(2015).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26754630; DOI=10.1186/s13046-016-0284-4;
RA   Hyakusoku H., Sano D., Takahashi H., Hatano T., Isono Y., Shimada S.,
RA   Ito Y., Myers J.N., Oridate N.;
RT   "JunB promotes cell invasion, migration and distant metastasis of head
RT   and neck squamous cell carcinoma.";
RL   J. Exp. Clin. Cancer Res. 35:6.1-6.12(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=28476783; DOI=10.21873/anticanres.11555;
RA   Hagemann J., Jacobi C., Hahn M., Schmid V., Welz C.,
RA   Schwenk-Zieger S., Stauber R.H., Baumeister P., Becker S.;
RT   "Spheroid-based 3D cell cultures enable personalized therapy testing
RT   and drug discovery in head and neck cancer.";
RL   Anticancer Res. 37:2201-2210(2017).
RX   PubMed=28844650; DOI=10.1016/j.anl.2017.07.011;
RA   Cho K.-J., Park E.-J., Kim M.-S., Joo Y.-H.;
RT   "Characterization of FaDu-R, a radioresistant head and neck cancer
RT   cell line, and cancer stem cells.";
RL   Auris Nasus Larynx 45:566-573(2017).
RX   PubMed=29156801; DOI=10.18632/oncotarget.21174;
RA   Kalu N.N., Mazumdar T., Peng S.-H., Shen L., Sambandam V., Rao X.-Y.,
RA   Xi Y.-X., Li L.-R., Qi Y., Gleber-Netto F.O., Patel A., Wang J.,
RA   Frederick M.J., Myers J.N., Pickering C.R., Johnson F.M.;
RT   "Genomic characterization of human papillomavirus-positive and
RT   -negative human squamous cell cancer cell lines.";
RL   Oncotarget 8:86369-86383(2017).
RX   PubMed=30135316; DOI=10.1172/jci.insight.122204;
RA   Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A.,
RA   Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D.,
RA   Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M.,
RA   Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R.,
RA   Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J.,
RA   McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G.,
RA   Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.;
RT   "Evofosfamide for the treatment of human papillomavirus-negative head
RT   and neck squamous cell carcinoma.";
RL   JCI Insight 3:e122204.1-e122204.19(2018).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31541927; DOI=10.1016/j.oraloncology.2019.09.004;
RA   van Harten A.M., Poell J.B., Buijze M., Brink A., Wells S.I.,
RA   Leemans C.R., Wolthuis R.M.F., Brakenhoff R.H.;
RT   "Characterization of a head and neck cancer-derived cell line panel
RT   confirms the distinct TP53-proficient copy number-silent subclass.";
RL   Oral Oncol. 98:53-61(2019).
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
RX   PubMed=33802339; DOI=10.3390/cancers13051069;
RA   Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.;
RT   "Genotyping and characterization of HPV status, hypoxia, and
RT   radiosensitivity in 22 head and neck cancer cell lines.";
RL   Cancers (Basel) 13:1069.1-1069.12(2021).
RX   PubMed=34249502; DOI=10.7717/peerj.11645;
RA   Zhang G.-H., Tan G.-L., Li T.-Q., Ai J.-G., Song Y.-X., Zhou Z.,
RA   Xiao J., Li W.;
RT   "Analysis of ceRNA network of differentially expressed genes in FaDu
RT   cell line and a cisplatin-resistant line derived from it.";
RL   PeerJ 9:e11645.1-e11645.15(2021).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).